Jeffrey W. Albers net worth and biography

Jeffrey Albers Biography and Net Worth

Jeff has more than 25 years of experience working in the biopharmaceutical industry and bringing important new medicines to patients with cancer and rare diseases. In 2014, he joined Blueprint Medicines as Chief Executive Officer and led the research-stage company through an initial public offering. Since that time, Blueprint Medicines has evolved into a leading precision medicine company with a global, fully integrated business, including two FDA-approved therapies and a rapidly advancing pipeline. Jeff previously served as President of Algeta, where he oversaw the successful commercial launch of a targeted cancer therapy prior to the company’s acquisition by Bayer. Prior to Algeta, he held senior commercial and corporate development positions at Genzyme (now a division of Sanofi), including vice president of the U.S. hematology and oncology business unit. Earlier in his career, Jeff was a life sciences corporate attorney at Mintz Levin Cohn Ferris Glovsky & Popeo. He currently serves on the board of directors at Magenta Therapeutics, Kymera Therapeutics and the Eastern New England Chapter of the American Cancer Society and is on the board of advisors for Life Sciences Cares. He holds a B.S. from Indiana University and an MBA and J.D. from Georgetown University.

What is Jeffrey W. Albers' net worth?: The estimated net worth of Jeffrey W. Albers is at least $15.23 million as of March 7th, 2024. Mr. Albers owns 165,017 shares of Blueprint Medicines stock worth more than $15,229,419 as of April 23rd. This net worth estimate does not reflect any other assets that Mr. Albers may own. Learn More about Jeffrey W. Albers' net worth.
How do I contact Jeffrey W. Albers?: The corporate mailing address for Mr. Albers and other Blueprint Medicines executives is 45 SIDNEY STREET, CAMBRIDGE MA, 02139. Blueprint Medicines can also be reached via phone at (617) 374-7580 and via email at [email protected]. Learn More on Jeffrey W. Albers' contact information.
Has Jeffrey W. Albers been buying or selling shares of Blueprint Medicines?: Jeffrey W. Albers has not been actively trading shares of Blueprint Medicines over the course of the past ninety days. Most recently, Jeffrey W. Albers sold 25,073 shares of the business's stock in a transaction on Wednesday, March 20th. The shares were sold at an average price of $87.28, for a transaction totalling $2,188,371.44. Following the completion of the sale, the director now directly owns 176,050 shares of the company's stock, valued at $15,365,644. Learn More on Jeffrey W. Albers' trading history.
Who are Blueprint Medicines' active insiders?: Blueprint Medicines' insider roster includes Jeffrey Albers (CEO), Percy Carter (Insider), George Demetri (Director), Debra Durso-Bumpus (Insider), Mark Goldberg (Director), Kate Haviland (COO), L. Hewes (Insider), Ariel Hurley (Insider), Michael Landsittel (CFO), Nicholas Lydon (Director), Tracey Mccain (EVP), Christopher Murray (Insider), Fouad Namouni (Insider), Christina Rossi (Insider), and Charles Rowland, Jr. (Director). Learn More on Blueprint Medicines' active insiders.
Are insiders buying or selling shares of Blueprint Medicines?: In the last twelve months, insiders at the biotechnology company sold shares 24 times. They sold a total of 172,543 shares worth more than $13,714,414.59. The most recent insider tranaction occured on March, 28th when CFO Michael Landsittel sold 5,000 shares worth more than $475,000.00. Insiders at Blueprint Medicines own 3.9% of the company. Learn More about insider trades at Blueprint Medicines.
Information on this page was last updated on 3/28/2024.

Jeffrey W. Albers Insider Trading History at Blueprint Medicines

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/20/2024	Sell	25,073	$87.28	$2,188,371.44	176,050
3/7/2024	Sell	11,033	$90.69	$1,000,582.77	165,017
1/25/2024	Sell	25,000	$81.91	$2,047,750.00	176,050
11/30/2023	Sell	5,000	$70.55	$352,750.00	176,050
11/24/2023	Sell	15,000	$67.51	$1,012,650.00	176,050
11/3/2023	Sell	1,485	$60.13	$89,293.05	176,050
11/1/2023	Sell	3,881	$60.02	$232,937.62	176,050
9/28/2023	Sell	6,898	$50.17	$346,072.66	176,050
8/25/2023	Sell	10,000	$50.16	$501,600.00	176,050
3/6/2023	Sell	9,793	$45.67	$447,246.31	173,450
12/5/2022	Sell	20,000	$50.09	$1,001,800.00	183,243
8/22/2022	Sell	8,410	$70.54	$593,241.40	183,243
8/19/2022	Sell	1,590	$70.02	$111,331.80	183,243
8/16/2022	Sell	20,000	$68.41	$1,368,200.00	183,243
8/8/2022	Sell	10,000	$70.07	$700,700.00	183,243
4/6/2022	Sell	5,000	$70.11	$350,550.00	183,243
11/15/2021	Sell	30,000	$114.50	$3,435,000.00
8/19/2021	Sell	25,000	$92.68	$2,317,000.00
5/12/2021	Sell	25,000	$92.69	$2,317,250.00	179,948
10/7/2020	Sell	5,000	$99.17	$495,850.00	146,434
5/12/2020	Sell	20,000	$64.67	$1,293,400.00	161,434
3/23/2020	Sell	20,000	$52.10	$1,042,000.00	141,434
11/18/2019	Sell	8,256	$75.42	$622,667.52	66,961
11/8/2019	Sell	11,744	$74.56	$875,632.64	66,961
8/19/2019	Sell	20,000	$81.73	$1,634,600.00	48,961
6/17/2019	Sell	5,000	$99.06	$495,300.00	33,961
6/12/2019	Sell	20,000	$84.75	$1,695,000.00	48,961
3/15/2019	Sell	20,000	$86.39	$1,727,800.00	48,961
11/5/2018	Sell	20,000	$63.49	$1,269,800.00	20,000
8/6/2018	Sell	20,000	$70.59	$1,411,800.00	20,000
5/7/2018	Sell	20,000	$78.90	$1,578,000.00	20,000
3/2/2018	Sell	20,000	$92.57	$1,851,400.00	20,000
11/6/2017	Sell	30,000	$70.31	$2,109,300.00
8/8/2017	Sell	30,000	$49.62	$1,488,600.00	18,272
8/7/2017	Sell	20,000	$49.08	$981,600.00	18,272
6/28/2017	Sell	20,000	$50.47	$1,009,400.00	47,920
8/8/2016	Sell	17,000	$22.86	$388,620.00	76,494
6/3/2016	Sell	17,000	$20.03	$340,510.00	92,486
4/6/2016	Sell	17,000	$20.42	$347,140.00	109,486

Jeffrey W. Albers Buying and Selling Activity at Blueprint Medicines

Blueprint Medicines Company Overview

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $91.87

$90.43

$91.88

50 Day Range

MA: $90.36

$76.80

$99.79

2 Week Range

Now: $91.87

$43.89

$101.00

Volume

18,824 shs

Average Volume

757,230 shs

Market Capitalization

$5.62 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.63

The "Smart Money" Is Ready for May 1st Are You?

From Stansberry Research | Ad

Former Wall Street VP: "Buy This Stock Now" Five of America's Most Successful Investors Bought Shares in The Same Company.

One Former Wall St. Trader Explains Why…